Better Therapeutics Appoints Deepti Sodhi Jaggi, PharmD, as Chief Strategy Officer
November 30 2021 - 8:00AM
Business Wire
Better Therapeutics, Inc. (“Better Therapeutics”; NASDAQ: BTTX),
a prescription digital therapeutics company developing cognitive
behavioral therapy to address the root causes of cardiometabolic
diseases, today announced the appointment of Deepti Sodhi Jaggi,
PharmD, as its Chief Strategy Officer.
“Deepti has spent her career driving innovation at the
intersection of healthcare and technology,” said Kevin Appelbaum,
co-founder and Chief Executive Officer. “She brings a unique mix of
intelligence, curiosity and courage to not be constrained by
precedent. I look forward to working closely with her to make our
vision of transforming the treatment of cardiometabolic diseases a
reality.”
Dr. Jaggi joins Better Therapeutics with decades of experience
focused on using technology to transform healthcare. Prior to
Better Therapeutics, she served as Global Head of Patient Insights
& Solutions at Astellas Pharmaceuticals and President &
Chief Medical Officer at Clinakos Inc. Previously, Dr. Jaggi worked
in business strategy roles for Johnson & Johnson, Genentech and
Oracle Corp, among various other positions. She currently serves as
a consultant to TPG Capital and sits on the Board of Directors for
Technology Credit Union.
“This new role at Better Therapeutics culminates the array of
expertise I’ve gained spanning the biopharma and technology
sectors, and I look forward to making a meaningful impact on the
lives of patients with cardiometabolic diseases working at this
groundbreaking company,” said Dr. Jaggi, Chief Strategy Officer at
Better Therapeutics. “This is a very forward-thinking and purpose
driven team, building software which could be a catalyst for change
in the way we address behavior-driven disease, and I’m honored to
offer my guidance to help us get there.”
Dr. Jaggi received her doctorate in pharmacy from the University
of Southern California and her MBA from Stanford University.
About Better Therapeutics Better Therapeutics is a
prescription digital therapeutics (PDT) company developing a novel
form of cognitive behavioral therapy to address the root causes of
cardiometabolic diseases. The company has developed a proprietary
platform for the development of FDA-regulated, software-based
solutions for type 2 diabetes, heart disease and other conditions.
The cognitive behavioral therapy delivered by Better Therapeutics’
PDT is designed to enable changes in neural pathways of the brain
so lasting changes in behavior become possible. Addressing the
underlying causes of these diseases has the potential to
dramatically improve patient health while lowering healthcare
costs. Better Therapeutics clinically validated mobile applications
are intended to be prescribed by physicians and reimbursed like
traditional medicines. For more information visit: bettertx.com
BTTX-PR
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211130005322/en/
Media Contact Heidi Chokeir heidi.chokeir@canalecomm.com
+1 619 203 5391
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Apr 2023 to Apr 2024